FDA Approves sNDA for Abuse Deterrent, Extended-Release Oxycodone – MD Magazine

The US Food and Drug Administration has approved a supplemental new drug application (sNDA) for an abuse-deterrent, extended-release oxycodone formula (Xtampza, Collegium Pharmaceutical) for the management of severe pain that requires daily, long-term opioid treatment.

The approval resulted in 3 main changes to the label. Pharmacokinetic, comparative data for the extended-release drug will be added, showing a comparison with the abuse-deterrent version (more…)

Cigna to stop covering most OxyContin prescriptions – CNN

“Our focus is on helping customers get the most value from their medications — this means obtaining effective pain relief while also guarding against opioid misuse,” Cigna Chief Pharmacy Officer Jon Maesner said in a statement Wednesday.

OxyContin is a brand name for an extended-release version of oxycodone, a commonly prescribed opioid painkiller.

Last year, Cigna set a goal of reducing its customers’ (more…)

Health insurance company stops covering OxyContin – WPTV.com

Health insurance company Cigna will no longer cover the painkiller drug OxyContin starting in 2018. This comes after the growing opioid addiction problem in the United States. Each year 15,000 people die from painkiller overdoses and 1,000 of those deaths are related to OxyContin.

We spoke with half a dozen pharmacists and addiction specialists who say they are happy to see steps (more…)